5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Neoplastic O
growth O
. O

There O
is O
a O
risk O
for O
acceleration O
of O
neoplastic O
growth O
. O

Colonoscopy O
of O
the O
entire O
colon O
with O
removal O
of O
polyps O
should O
be O
done O
before O
initiating O
treatment O
with O
GATTEX O
and O
is O
recommended O
after O
1 O
year O
. O

Subsequent O
colonoscopies O
should O
be O
done O
as O
needed O
, O
but O
no O
less O
frequently O
than O
every O
5 O
years O
. O

In O
case O
of O
intestinal O
malignancy O
discontinue O
GATTEX O
. O

The O
clinical O
decision O
to O
continue O
GATTEX O
in O
patients O
with O
non-gastrointestinal O
malignancy O
should O
be O
made O
based O
on O
risk O
and O
benefit O
considerations O
. O

( O
5.1 O
) O
* O
Intestinal O
obstruction O
. O

In O
patients O
who O
develop O
obstruction O
, O
GATTEX O
should O
be O
temporarily O
discontinued O
pending O
further O
clinical O
evaluation O
and O
management O
. O

( O
5.2 O
) O
* O
Biliary O
and O
pancreatic O
disease O
. O

Patients O
should O
undergo O
laboratory O
assessment O
( O
bilirubin O
, O
alkaline O
phosphatase O
, O
lipase O
, O
amylase O
) O
before O
starting O
GATTEX O
. O

Subsequent O
laboratory O
tests O
should O
be O
done O
every O
6 O
months O
. O

If O
clinically O
meaningful O
changes O
are O
seen O
, O
further O
evaluation O
is O
recommended O
including O
imaging O
, O
and O
continued O
treatment O
with O
GATTEX O
should O
be O
reassessed O
. O

( O
5.3 O
) O
* O
Fluid O
overload O
. O

There O
is O
a O
potential O
for O
fluid O
overload O
while O
on O
GATTEX O
. O

If O
fluid O
overload O
occurs O
, O
especially O
in O
patients O
with O
cardiovascular O
disease O
, O
parenteral O
support O
should O
be O
appropriately O
adjusted O
, O
and O
GATTEX O
treatment O
reassessed O
. O

( O
5.4 O
) O
5.1 O
Acceleration O
of O
Neoplastic O
Growth O
Based O
on O
the O
pharmacologic O
activity O
and O
findings O
in O
animals O
, O
GATTEX O
has O
the O
potential O
to O
cause O
hyperplastic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
including O
neoplasia B-OSE_Labeled_AE
. O

In O
patients O
at O
increased O
risk O
for O
malignancy B-NonOSE_AE
, O
the O
clinical O
decision O
to O
use O
GATTEX O
should O
be O
considered O
only O
if O
the O
benefits O
outweigh O
the O
risks O
. O

In O
patients O
with O
active O
gastrointestinal B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
( O
GI O
tract O
, O
hepatobiliary O
, O
pancreatic O
) O
, O
GATTEX O
therapy O
should O
be O
discontinued O
. O

In O
patients O
with O
active O
non B-NonOSE_AE
- I-NonOSE_AE
gastrointestinal I-NonOSE_AE
malignancy I-NonOSE_AE
, O
the O
clinical O
decision O
to O
continue O
GATTEX O
should O
be O
made O
based O
on O
risk-benefit O
considerations O
. O

[ O
see O
Clinical O
Pharmacology O
( O
12.1 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
Colorectal O
Polyps O
Colorectal B-OSE_Labeled_AE
polyps I-OSE_Labeled_AE
were O
identified O
during O
the O
clinical O
trials O
. O

Colonoscopy O
of O
the O
entire O
colon O
with O
removal O
of O
polyps B-NonOSE_AE
should O
be O
done O
within O
6 O
months O
prior O
to O
starting O
treatment O
with O
GATTEX O
. O

A O
follow-up O
colonoscopy O
( O
or O
alternate O
imaging O
) O
is O
recommended O
at O
the O
end O
of O
1 O
year O
of O
GATTEX O
. O

Subsequent O
colonoscopies O
should O
be O
done O
every O
5 O
years O
or O
more O
often O
as O
needed O
. O

If O
a O
polyp B-NonOSE_AE
is O
found O
, O
adherence O
to O
current O
polyp B-NonOSE_AE
follow-up O
guidelines O
is O
recommended O
. O

In O
case O
of O
diagnosis O
of O
colorectal B-NonOSE_AE
cancer I-NonOSE_AE
, O
GATTEX O
therapy O
should O
be O
discontinued O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
Small B-OSE_Labeled_AE
Bowel I-OSE_Labeled_AE
Neoplasia I-OSE_Labeled_AE
Based O
on O
benign B-NonOSE_AE
tumor I-NonOSE_AE
findings O
in O
the O
rat O
carcinogenicity B-NonOSE_AE
study O
, O
patients O
should O
be O
monitored O
clinically O
for O
small B-NonOSE_AE
bowel I-NonOSE_AE
neoplasia I-NonOSE_AE
. O

If O
a O
benign B-NonOSE_AE
neoplasm I-NonOSE_AE
is O
found O
, O
it O
should O
be O
removed O
. O

In O
case O
of O
small B-NonOSE_AE
bowel I-NonOSE_AE
cancer I-NonOSE_AE
, O
GATTEX O
therapy O
should O
be O
discontinued O
. O

[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
5.2 O
Intestinal O
Obstruction O
Intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
has O
been O
reported O
in O
clinical O
trials O
. O

In O
patients O
who O
develop O
intestinal B-NonOSE_AE
or O
stomal O
obstruction I-NonOSE_AE
, O
GATTEX O
should O
be O
temporarily O
discontinued O
while O
the O
patient O
is O
clinically O
managed O
. O

GATTEX O
may O
be O
restarted O
when O
the O
obstructive O
presentation O
resolves O
, O
if O
clinically O
indicated O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
5.3 O
Biliary O
and O
Pancreatic O
Disease O
Gallbladder O
and O
Biliary O
Tract O
Disease O
Cholecystitis B-OSE_Labeled_AE
, O
cholangitis B-OSE_Labeled_AE
, O
and O
cholelithiasis B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
clinical O
studies O
. O

For O
identification O
of O
the O
onset O
or O
worsening O
of O
gallbladder B-NonOSE_AE
/biliary O
disease I-NonOSE_AE
, O
patients O
should O
undergo O
laboratory O
assessment O
of O
bilirubin O
and O
alkaline O
phosphatase O
within O
6 O
months O
prior O
to O
starting O
GATTEX O
, O
and O
at O
least O
every O
6 O
months O
while O
on O
GATTEX O
; O
or O
more O
frequently O
if O
needed O
. O

If O
clinically O
meaningful O
changes O
are O
seen O
, O
further O
evaluation O
including O
imaging O
of O
the O
gallbladder O
and/or O
biliary O
tract O
is O
recommended O
; O
and O
the O
need O
for O
continued O
GATTEX O
treatment O
should O
be O
reassessed O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
Pancreatic O
Disease O
Pancreatitis B-OSE_Labeled_AE
has O
been O
reported O
in O
clinical O
studies O
. O

For O
identification O
of O
onset O
or O
worsening O
of O
pancreatic B-NonOSE_AE
disease I-NonOSE_AE
, O
patients O
should O
undergo O
laboratory O
assessment O
of O
lipase O
and O
amylase O
within O
6 O
months O
prior O
to O
starting O
GATTEX O
, O
and O
at O
least O
every O
6 O
months O
while O
on O
GATTEX O
; O
or O
more O
frequently O
if O
needed O
. O

If O
clinically O
meaningful O
changes O
are O
seen O
, O
further O
evaluation O
such O
as O
imaging O
of O
the O
pancreas O
is O
recommended O
; O
and O
the O
need O
for O
continued O
GATTEX O
treatment O
should O
be O
reassessed O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
5.4 O
Fluid O
Overload O
Fluid B-OSE_Labeled_AE
overload I-OSE_Labeled_AE
and O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
have O
been O
observed O
in O
clinical O
trials O
, O
which O
were O
felt O
to O
be O
related O
to O
enhanced O
fluid O
absorption O
associated O
with O
GATTEX O
. O

If O
fluid B-NonOSE_AE
overload I-NonOSE_AE
occurs O
, O
parenteral O
support O
should O
be O
adjusted O
and O
GATTEX O
treatment O
should O
be O
reassessed O
, O
especially O
in O
patients O
with O
underlying O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

If O
significant O
cardiac B-NonOSE_AE
deterioration I-NonOSE_AE
develops O
while O
on O
GATTEX O
, O
the O
need O
for O
continued O
GATTEX O
treatment O
should O
be O
reassessed O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
5.5 O
Increased O
Absorption O
of O
Concomitant O
Oral O
Medication O
Altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
in O
association O
with O
GATTEX O
has O
been O
observed O
in O
patients O
on O
benzodiazepines O
in O
clinical O
trials O
. O

Patients O
on O
concomitant O
oral O
drugs O
( O
e.g. O
, O
benzodiazepines O
, O
phenothiazines O
) O
requiring O
titration O
or O
with O
a O
narrow O
therapeutic O
index O
may O
require O
dose O
adjustment O
while O
on O
GATTEX O
. O

[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O

